Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4424-4428

  Cumpston, Aaron ^a,b   Caddell, Ryan ^a   Shillingburg, Alexandra ^a,b   Lu, Xiaoxiao ^b   Wen, Sijin ^b   Hamadani, Mehdi ^c   Craig, Michael ^b   Kanate, Abraham S ^b  

^a WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; ANTIFUNGAL AGENT; DELAYED RELEASE FORMULATION; SUSPENSION; TABLET; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER PATIENT; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG USE; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYCOSIS; MYELODYSPLASTIC SYNDROME; NUTRITIONAL STATUS; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; SUSPENSION; TABLET FORMULATION; TOXICITY TESTING; TREATMENT OUTCOME; VOMITING; ADMINISTRATION AND DOSAGE; ADOLESCENT; BLOOD; HEMATOLOGIC DISEASE; MEDICINAL CHEMISTRY; MICROBIOLOGY; MIDDLE AGED; MYCOSES; PROCEDURES; TABLET; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; SUSPENSIONS; TABLETS; TRIAZOLES; YOUNG ADULT;

EID: 84939863729     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00581-15     Document Type: Article

References (17)

1. Merck & Co., Inc. 2012. Noxafil (posaconazole) package insert. Merck & Co., Inc., Whitehouse Station, NJ.
2. Krishna G, Abu Tarif M, Xuan F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myeloplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592/phco.28.10.1223.
3. Lebeaux D, Lanternier F, Elie C, Suarez F, Buzyn A, Viard JP, Bougnoux ME, Lecuit M, Jullien V, Lortholary O. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 53:5224-5229. http://dx.doi.org/10.1128/AAC.00939-09.
4. AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin 26:397-405. http://dx.doi.org/10.1185/03007990903485056.
5. Kohl V, Muller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJ. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 54:207-212. http://dx.doi.org/10.1128/AAC.01027-09.
6. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218-222. http://dx.doi.org/10.1046/j.1365-2125.2003.01977.x.
7. Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M. 2012. Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. Int J Antimicrob Agents 40:557-561. http://dx.doi.org/10.1016/j.ijantimicag.2012.09.001.
8. Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM. 2014. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 58:4020-4025. http://dx.doi.org/10.1128/AAC.02448-13.
9. Krishna G, Ma L, Martinho M, O'Mara E. 2012. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 56:4196-4201. http://dx.doi.org/10.1128/AAC.00222-12.
10. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. 2012. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 67:2725-2730. http://dx.doi.org/10.1093/jac/dks268.
11. Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H. 2014. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58:5758-5765. http://dx.doi.org/10.1128/AAC.03050-14.
12. Courtney RS, Pai S, Laughlin M, Lim J, Batra V. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47:2788-2895. http://dx.doi.org/10.1128/AAC.47.9.2788-2795.2003.
13. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. 2014. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162-1176. http://dx.doi.org/10.1093/jac/dkt508.
14. Heinz WJ, Zirkel J, Kuhn A, Schirmer D, Lenker U, Keller D, Klinker H. 2011. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother 55:3621-3623. http://dx.doi.org/10.1128/AAC.00062-11.
15. National Cancer Institute. 2009. Common terminology criteria for adverse events (CTCAE), v4.0. National Cancer Institute, Bethesda, MD.
16. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821. http://dx.doi.org/10.1086/588660.
17. Jung DS, Tverdek FP, Kontoyiannis DP. 2014. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother 58:6993-6995. http://dx.doi.org/10.1128/AAC.04035-14.